ArticleJournal of clinical & translational endocrinology2025
Can ACR TI-RADS predict the malignant risk of medullary thyroid cancer?
Article in Journal of clinical & translational endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluating the clinical impact of integrating superb microvascular imaging and shear wave elastography into TI-RADS.Journal of ultrasound · 2025Article
- Using Elastographic Stiffness to Improve Risk Stratification in Medullary Thyroid Carcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- Preoperative identification of the risk factors of cervical lymph node metastasis in medullary thyroid carcinoma.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to evaluate the diagnostic performance for medullary thyroid cancer (MTC) based on the 2017 Thyroid Imaging Reporting and Data System by the American College of Radiology (ACR TI-RADS) guideline, and the ability to recommend fine needle aspiration (FNA) for MTC. Methods: Fifty-six MTCs were included, and 168 benign thyroid nodules (BTNs) and 168 papillary thyroid nodules (PTCs) were matched according to age. Ultrasound (US) features were reviewed according to ACR TI-RADS. US, clinical features and diagnostic performance of cytology of MTC, BTN and PTC were compared. Multivariate logistic regression analysis was performed to assess independent variables to predict MTC. Results: Multivariate logistic regression showed that position, hypoechoic, AP/T ratio ≥ 0.9 and marked internal blood flow were independent predictors of MTC compared to BTN (P < 0.05) and nodule sizes, AP/T ratio < 1, smooth or ill-defined margin and marked internal blood flow were independent predictors of MTC compared to PTC (P < 0.05). The area under the receiver operating characteristic (ROC) curve (AUC) of MTC based on ACR TI-RADS was inferior to that of PTC (0.687 vs 0.823) (P < 0.001). The recommended rate of FNA for MTC and PTC was 55.4 and 88.7 % respectively. 8 of 14 MTCs with negative FNA results (Bethesda II) had abnormal calcitonin (Ctn) results. Conclusions: Based on the ACR TI-RADS classification, the malignant risk features of MTC were intermediate between BTN and PTC. The diagnostic efficacy of MTC and FNA recommendation rate were inferior to PTC. Ctn examination would reduce the FNA missed diagnosis of MTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.